Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Home
<
List for "N06DA03" (35)
–
Sort according to Concentration, Size and Price
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
Rivastigmine (N06DA03) 35 products
WHO-DDD
DrugBank.ca
L
IP
CI
CM
Rivastigmin Patch Sandoz 5
30
39.51
59.40
10 %
Transdermal patch: Rivastigminum 9 mg
Sandoz
Pharmaceuticals AG
B / SL / SG
FB
G
L
IP
CI
CM
Rivastigmin Patch Sandoz 10
30
39.51
59.40
10 %
Transdermal patch: Rivastigminum 18 mg
Sandoz
Pharmaceuticals AG
B / SL / SG
FB
G
L
IP
CI
CM
Rivastigmin Patch Sandoz 10
60
79.02
102.35
10 %
Transdermal patch: Rivastigminum 18 mg
Sandoz
Pharmaceuticals AG
B / SL / SG
FB
G
L
IP
CM
Rivastigmin Patch Sandoz 15
30
39.51
59.40
10 %
Transdermal patch: Rivastigminum 27 mg
Sandoz
Pharmaceuticals AG
B / SL / SG
FB
G
L
IP
CM
Rivastigmin Patch Sandoz 15
60
79.02
102.35
10 %
Transdermal patch: Rivastigminum 27 mg
Sandoz
Pharmaceuticals AG
B / SL / SG
FB
G
Rivasur zweimal
wöchentlich 4,6 mg/24
Stunden
8
PR
PR
k.A.
Transdermal patch: (Transdermales Pflaster): Rivastigminum 25.92 mg
Luye Pharma
Switzerland AG
B
FB
G
Rivasur zweimal
wöchentlich 4,6 mg/24
Stunden
16
PR
PR
k.A.
Transdermal patch: (Transdermales Pflaster): Rivastigminum 25.92 mg
Luye Pharma
Switzerland AG
B
FB
G
Rivasur zweimal
wöchentlich 9,5 mg/24
Stunden
8
PR
PR
k.A.
Transdermal patch: (Transdermales Pflaster): Rivastigminum 51.84 mg
Luye Pharma
Switzerland AG
B
FB
G
Rivasur zweimal
wöchentlich 9,5 mg/24
Stunden
16
PR
PR
k.A.
Transdermal patch: (Transdermales Pflaster): Rivastigminum 51.84 mg
Luye Pharma
Switzerland AG
B
FB
G
L
IP
CI
Exelon Patch 5
30 plaster(s)
53.24
73.45
20 %
Transdermal patch: Rivastigminum 9 mg
Novartis Pharma
Schweiz AG
B / SL / SO
FB
G
L
IP
CI
Exelon Patch 10
30 plaster(s)
53.24
73.45
20 %
Transdermal patch: Rivastigminum 18 mg
Novartis Pharma
Schweiz AG
B / SL / SO
FB
G
L
IP
CI
Exelon Patch 10
60 plaster(s)
106.48
130.55
20 %
Transdermal patch: Rivastigminum 18 mg
Novartis Pharma
Schweiz AG
B / SL / SO
FB
G
L
IP
CI
Exelon Patch 15
30 plaster(s)
53.24
73.45
20 %
Transdermal patch: Rivastigminum 27 mg
Novartis Pharma
Schweiz AG
B / SL / SO
FB
G
L
IP
CI
Exelon Patch 15
60 plaster(s)
106.48
130.55
20 %
Transdermal patch: Rivastigminum 27 mg
Novartis Pharma
Schweiz AG
B / SL / SO
FB
G
L
IP
CI
Rivastigmin Zentiva Patch 4.6
mg/24 h
30
39.51
59.40
10 %
Transdermal patch: Rivastigminum 6.9 mg
Helvepharm AG
B / SL / SG
FB
G
L
IP
CI
Rivastigmin Zentiva Patch 9.5
mg/24 h
30
39.51
59.40
10 %
Transdermal patch: Rivastigminum 13.8 mg
Helvepharm AG
B / SL / SG
FB
G
L
IP
CI
Rivastigmin Zentiva Patch 9.5
mg/24 h
2 x 30
79.02
102.35
10 %
Transdermal patch: Rivastigminum 13.8 mg
Helvepharm AG
B / SL / SG
FB
G
L
IP
Rivastigmin Zentiva Patch
13.3 mg/24 h
30
39.51
59.40
10 %
Transdermal patch: Rivastigminum 19.2 mg
Helvepharm AG
B / SL / SG
FB
G
L
IP
Rivastigmin Zentiva Patch
13.3 mg/24 h
2 x 30
79.02
102.35
10 %
Transdermal patch: Rivastigminum 19.2 mg
Helvepharm AG
B / SL / SG
FB
G
L
IP
CI
Rivastigmin-Mepha Patch 4.6
mg/24 h
30
39.51
59.40
10 %
Transdermale Pflaster: Rivastigminum 6.4 mg
Mepha Pharma AG
B / SL / SG
FB
G
L
IP
Rivastigmin-Mepha Patch 9.5
mg/24 h
30
39.51
59.40
10 %
Transdermale Pflaster: Rivastigminum 12.8 mg
Mepha Pharma AG
B / SL / SG
FB
G
L
IP
Rivastigmin-Mepha Patch 9.5
mg/24 h
2 x 30
79.02
102.35
10 %
Transdermale Pflaster: Rivastigminum 12.8 mg
Mepha Pharma AG
B / SL / SG
FB
G
L
IP
Rivastigmin-Mepha Patch
13.3 mg/24 h
30
39.51
59.40
10 %
Transdermale Pflaster: Rivastigminum 19.2 mg
Mepha Pharma AG
B / SL / SG
FB
G
L
IP
Rivastigmin-Mepha Patch
13.3 mg/24 h
2 x 30
79.02
102.35
10 %
Transdermale Pflaster: Rivastigminum 19.2 mg
Mepha Pharma AG
B / SL / SG
FB
G
L
IP
CI
Exelon 1,5 mg
-
T
28 Capsule(s)
23.73
42.20
10 %
Capsules: Rivastigminum 1.5 mg
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
CI
Exelon 1,5 mg
-
T
56 Capsule(s)
42.53
62.65
10 %
Capsules: Rivastigminum 1.5 mg
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
CI
Exelon 1,5 mg
-
T
112 Capsule(s)
93.27
117.85
10 %
Capsules: Rivastigminum 1.5 mg
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
CI
Exelon 3 mg
-
T
28 Capsule(s)
23.73
42.20
10 %
Capsules: Rivastigminum 3 mg
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
CI
Exelon 3 mg
-
T
56 Capsule(s)
42.53
62.65
10 %
Capsules: Rivastigminum 3 mg
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
CI
Exelon 3 mg
-
T
112 Capsule(s)
93.27
117.85
10 %
Capsules: Rivastigminum 3 mg
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
CI
Exelon 4,5 mg
-
T
28 Capsule(s)
23.73
42.20
10 %
Capsules: Rivastigminum 4.5 mg
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
CI
Exelon 4,5 mg
-
T
112 Capsule(s)
93.27
117.85
10 %
Capsules: Rivastigminum 4.5 mg
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
CI
Exelon 6 mg
-
T
28 Capsule(s)
23.73
42.20
10 %
Capsules: Rivastigminum 6 mg
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
CI
Exelon 6 mg
-
T
112 Capsule(s)
93.27
117.85
10 %
Capsules: Rivastigminum 6 mg
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
CI
Exelon 2 mg/ml
120 ml
68.98
91.45
10 %
Solution (oral): Rivastigminum 2 mg/ml
Novartis Pharma
Schweiz AG
B / SL
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2025
©ywesee GmbH
Settings
|
Help
|
FAQ
|
Login
|
Contact
|
Home